Jump to content

triplehorn

Full Members
  • Posts

    4441
  • Joined

  • Last visited

Posts posted by triplehorn

  1. Per the NIH algorithm I referenced above, and the absence of any recommendation for treatment of early disease in uncomplicated outpatient cases of sars-cov2, realize that this absence of early outpatient intervention appears to be largely what separates us (and western Europe) in terms of outcomes related to deaths/1M population and our demonstrably worse results by comparison overall from countries and regions that actively and widely employ a variety early outpatient treatments.

    3 days ago, Dr. Peter A. McCullough MD MPH, Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX, UT Southwestern Med grad, and prominent investigator in clinical research, gave a webinar on the rationale and options for early outpatient intervention with Covid infection. 

    Notably, he is actively infected with covid this week and gave the webinar from home to an international audience while clearly symptomatic (first 30-45min are the meat of it):

    Outpatient Early Treatment Algorithm for COVID-19 - a Webinar with Dr Peter A. McCullough

    now go back and look at that NIH algorithm.

     

  2. Business and politics in a pandemic:

    The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug

     

    Read the article above.  Now look at the official current NIH recommendations today:

     

    Quote

    Ek-gtlWUUAI7vt4?format=jpg&name=900x900

    First, note that there is no recommendation for any antiviral or immunomodulatory therapy for early uncomplicated disease.  Yet notice how remdesivir somehow gets a mention in that box.  Not only that, Remdesivir gets a mention in every box.  Now go read the article linked above again.  Who exactly had a hand in crafting this NIH algorithm?  Either way, Gilead certainly strongly approves.

  3. In addition to "modest reductions can translate into large differences over time," implementing the mask and distancing measures as early as possible similarly massively alters the exponential trajectory.  The difference in the number of cases after one month between two scenarios where the difference between measures being started is only one or two days is staggering.  The battle was lost in Feb/March.  

     

     
  4. - In Philly last night, a van packed with explosives was found (no positive attribution as of now). 

    - This morning FBI made surprise arrests of 2 more militant white supremacists in Michigan.

    - Also last night in Philly, 16 U-Haul trucks were stolen in addition to propane tanks (again no positive attribution as of now).

    my only question is if 16 U-Haul trucks is enough to spell out "TMcV" when seen from above.

     

  5. 13 minutes ago, Red Five said:

    Holy shit. 

    It’s not unreasonable to estimate the risk as ‘high’ right now.  In case you missed it, a potential OKC type bombing may have been foiled in Philly in the dead of night this morning.  Considering  PA is seen as THE pivotal state by Trump, throwing the state election into chaos could be used as an opportunity for god knows what to steal it.  It’s a target rich environment for the incited.

  6. 23 minutes ago, Brisketexan said:

    tenor.gif

    If you push the costs of an activity of a few onto the society of a whole.....that's squarely within the definition of socialism.  You are literally socializing costs.

    If you let a private enterprise impose those costs on society, and keep the profits they made/money they saved by imposing those costs on the public, that's kleptocracy.

    When you then apply it to the Trump GOP model, and you realize that they have managed to create a perfect toxic stew of socialized costs, kleptocratic gains, and fascist systems of order to keep that train going, well, you oughta puke.

    Take it a step further -Trump tariffs choked American farmers and shifted the market supply for China from US to...take a guess...then heaped taxpayer dollars on said farmers for emergency relief as certain foreign locales profited from American farmers’ loss.

    It’s the kind of thing you might expect if a foreign power is propping up a third of a billion of your personal debt.

    • Hook 'Em 1
  7. 25 minutes ago, Hiphopopotamos said:

    There are going to be way too many people who are going to call for 'unity' and 'healing' and who will want to put this dark chapter behind us and 'help move the country forward'.

    Fuck that.

    They need to start hauling these assholes up in front of the Senate - and then they need to start bringing charges.  They need to make the Benghazi hearing look tame by comparison.  Every single one of these assholes need to be held accountable for the corruption and the human rights abuses.

    They need to make an example of Barr so that no future AG gets the idea that he can act as the president's personal attorney.

    If it’s true that Biden intends to serve only one term if he wins, might as well wield some high level justice.  Otherwise the same cockroaches absolutely will survive to unleash the same fuckery all over again.  

    • Like 1
  8. also reported by Stedman: Russian Intelligence Connected Bank Deposited $330M Into Deutsche Bank America

    "A small financial institution in Russia whose owner has been called a “front” for Russian intelligence services quietly moved $330 million dollars into an account at Deutsche Bank’s New York branch by 2013, according to documents exclusively obtained by Forensic News.

    By the fall of 2013, Yugra Bank (or “Jugra”; “Ugra”) was the 106th largest bank in Russia, with just eight branch locations in the country. A small bank by any measure, Yugra Bank was akin to “Bank of Hope” in the United States in terms of assets.

    But interviews with those familiar with Yugra Bank and its evasive oligarch owner, as well as exclusively obtained documents, shed light on how this small regional bank in Russia was able to quietly transfer nearly one-third of a billion dollars into a Deutsche Bank subsidiary on Wall Street in New York.  [cont.]"

    ---> 2013 is when the foreign plan to help get Trump elected was launched, as described by Felix Sater and others.  And this says nothing about the $15M that suddenly appeared in 2015 in a secret Trump LLC bank account in China (revealed in recent NYT obtained tax documents) after the previous 4 years of that unknown LLC earnings being flat.  There's likely an avalanche of redundancy of this kind of financial leverage (including plain bribery) foreign powers have over Trump 'the individual' that also includes Middle East actors.

  9. 12 minutes ago, Bookman said:

    Banks don’t lend to Trump. They haven’t for years.
     

    Deutsche Bank tho

    Quote

     

     

    If there are publicly unknown third parties working with DB to guarantee Trump's loans, then those third parties own the fucker.  Available information points to exactly that.

  10. ‘A mass exodus’: HHS staffers jumping ship amid pandemic, fears of Trump loss

    "I've personally seen people working on their resumes inside the office," the senior official added. "It's no secret."

    While there are typically a slew of political departures in the run-up to an election, this year's HHS defections have been unusually prominent and have touched every corner of a health department that's been barraged by pandemic-linked pressures. 

     

    Spoiler

    Skydivers-Human-Ring.gif

     

    • Haha 1
  11. On 10/16/2020 at 7:20 AM, Hmbre97 said:

    HIV/AIDS isn't just an issue in the US...

    I've been meaning to come back to table to clarify regarding 35% of NIAID (headed by Dr. Fauci) going to HIV and HIV vaccine grants:

    Quote

    EkJg55CXkAYwWv8?format=jpg&name=medium

    HIV research is important for the US and for the world.  Does it warrant a full third of NIAID funding?  I don't know.  But one thing to consider is that HIV is the infectious disease that defines Anthony Fauci's three decades of tenure as head of the NIAID.  I've never been one to harp on the downsides of bureaucrats, but Fauci appears to embody the definition of a DC bureaucrat.  That comes with a risk of overly adhering to what you know and what is familiar at the expense of efficiency or common sense.  And it's not that Fauci lacks common sense, but rather that this pandemic is new and complex and the decision making process appears to be overly concentrated to small number of individuals.  Fauci isn't a bad guy, but 30 year bureaucrats can represent a risk for latent individual bias and narrows the target field for special interests to influence process.

    Therapeutics for Covid account for 10% of the Covid budget.  But even that number is misleading because apparently 75% of that 10% for therapeutics has been dedicated to a Lilly monoclonal antibody essentially unproven for safety or efficacy.  In the US, the percent of funds used to research re-purposed drugs that already have FDA safety approval is basically non-existent.  I think one result of that is in part reflected by our abysmal rate of deaths/1M population.  Countries that have been broadly and aggressively using re-purposed generics in early outpatient Covid illness are greatly outperforming the US and the EU in general.  The volume of research being done by the US for re-purposed drugs is dwarfed by the number of studies being done in "lesser" countries that are kicking our butts in terms of actually saving lives while we wait for a new vaccine.

  12.  

    Re allocation of 2020 funding for the National Institute of Allergy and Infectious Diseases (NIAID) which Dr. Fauci has headed for decades, this is interesting:

     

    EkJg55CXkAYwWv8?format=jpg&name=medium

    A whopping 81% of funds for Covid is going to vaccine research.

    A mere 4% is allocated for therapeutics research which relates to studies like re-purposing drugs to treat Covid to save lives that have been lost daily since March and includes understanding application of things like VitD3, famotidine, invermectin, hcq/cq, etc.  Of that 4% of NIAID budget allocated for therapeutics, 75% of that went to Lilly’s monoclonal antibody. 

    It's not that the there is no evidence favoring repurposed generics as the mountain of international studies demonstrate, it's that the NIAID decided at inception to bail on understanding the whole lot and going all in on vaccines.  Meanwhile 200k+ dead Americans and counting.

    Also note HIV still receiving a whopping 35% of total NIAID funds, accounting for 0.3 deaths per Million US pop. by 2007.  

  13. 5 minutes ago, Hugo Stiglitz said:

    How the Republicans rebound after Trump is going to have a lot to do with how the Democrats in office behave.  Like Lucy with the football, the Republicans are going to get away with whatever they can.  They will lie and say they never liked Trump or that Trump was holding the party hostage and they just want to get back to the way things used to be.  It will be the duty of the democrats to not tolerate that shit and call them out.  The GOP has shown the world exactly who they are and democrats will need to make sure America does not forget. 

    They'll all be about looking forward, not backward

     

  14. 17 hours ago, 4th&Five said:

     

     

    When it comes to combating viruses, "Hit It Early and Hard" is the mantra.  That applies to altering population behavior as well as medical intervention.  Things that work early don't work so well, or at all, when started too late.  

    It took 10 months for him to parrot it, even though he still doesn't fully get it, or recognize how badly he failed our country as a result.

  15. 51 minutes ago, Sawbonz said:

    I wonder if readers will perceive a difference between shilling for Big Pharma and expressing concern for the health of millions? Yeah probably not

    At the risk of misinterpreting you, generally the art of influence is not black and white and the targets aren't always obvious by design.  So yeah, in this case readers (the public, medical community, political establishment) not perceiving the difference between being a shill for political influence versus expressing genuine concern would be the goal.  What journals publish, including the NEJM, is significantly influenced by pharma's business interests, as the former editor-in-chief of the NEJM experienced first hand from the inside.  So the supposition is not just out of left field.  And this move by the NEJM is sufficiently irregular to warrant considering additional explanations.  

  16. I'm not making a claim or accusation about the NEJM or those who penned the article, but as an exercise, consider what former NEJM editor in chief  Dr. Marcia Angell wrote about big pharma in her book The Truth About the Drug Companies: 

    Spoiler

    - The boundaries between academic medicine — medical schools, teaching hospitals, and their faculty — and the pharmaceutical industry have been dissolving since the 1980s, and the important differences between their missions are becoming blurred. Medical research, education, and clinical practice have suffered as a result.

    - “To a remarkable extent … medical centers have become supplicants to the drug companies, deferring to them in ways that would have been unthinkable even twenty years ago. Often, academic researchers are little more than hired hands who supply human subjects and collect data according to instructions from corporate paymasters. The sponsors keep the data, analyze it, write the papers, and decide whether and when and where to submit them for publication. In multi-center trials, researchers may not even be allowed to see all of the data, an obvious impediment to science and a perversion of standard practice."

    - “[Drug] manufacturers typically prefer to work with academic medical centers. Doing so increases the chances of getting research published, and, more importantly, provides drug companies access to highly influential faculty physicians — referred to by the industry as ‘thought leaders’ or ‘key opinion leaders.’ These are the people who write textbooks and medical-journal papers, issue practice guidelines (treatment recommendations), sit on FDA and other governmental advisory panels, head professional societies, and speak at the innumerable meetings and dinners that take place every day to teach clinicians about prescription drugs.”

    - “Medical centers increasingly act as though meeting industry’s needs is a legitimate purpose of an academic institution…. Academic leaders, chairs, and even deans sit on boards of directors of drug companies. Many academic medical centers have set up special offices to offer companies quick soup-to-nuts service.”

    - “Increasingly, industry is setting the research agenda in academic centers, and that agenda has more to do with industry’s mission than with the mission of the academy. Researchers and their institutions are focusing too much on targeted, applied research, mainly drug development, and not enough on non-targeted, basic research into the causes, mechanisms, and prevention of disease.”

    -  “[D]rug companies often contract with academic researchers to carry out studies for almost entirely commercial purposes. For example, they sponsor trials of drugs to supplant virtually identical ones that are going off patent…. There’s a high scientific opportunity cost in serving the aims of the pharmaceutical industry. For example, new antibiotics for treating infections by resistant organisms are an urgent medical need, but are not economically attractive to industry because they are not likely to generate much return on investment.”

    - “In addition to distorting the research agenda, there is overwhelming evidence that drug-company influence biases the research itself. Industry-supported research is far more likely to be favorable to the sponsors’ products than in NIH-supported research.”

    - “Conflicts of interest affect more than research. They also directly shape the way medicine is practiced, through their influence on practice guidelines issued by professional and governmental bodies and through their effects on FDA decisions.” Angell offers several examples, including this one: “In 2004, after the NIH National Cholesterol Education Program called for sharply lowering the acceptable levels of ‘bad’ cholesterol, it was revealed that eight of nine members of the panel writing the recommendations had financial ties to the makers of cholesterol-lowering drugs.”

    -“Drug companies support educational programs even within our best medical schools and teaching hospitals, and are given virtually unfettered access to young doctors to ply them with gifts and meals and promote their wares. … This is marketing masquerading as education. … But doctors do learn something from all the ostensible education they’re paid to receive. Doctors and their patients come to believe that for every ailment and discontent there is a drug, even when changes in lifestyle would be more effective. And they believe that the newest, most expensive brand-name drugs are superior to older drugs or generics, even though there is seldom any evidence to that effect because sponsors don’t usually compare their drugs with older drugs at equivalent doses.”

    etc.

    The exercise is to think of what the politicized article means if the substance and timing is being externally promulgated by big pharma interests as opposed to sacrosanct elements of the NEJM.  In this case, the targeted audience would be the Democratic political establishment that appears to be poised for wins next month and utilizing the powerful 'principle of reciprocity' to curry policy favor, if not to garner a degree of loyalty from those expected soon to be at the helm making real time decisions that have billions in the balance for pharma going forward.  Ordinarily, big corporate donations hedge and go to both sides.  The timing of this from NEJM is what seems a little suspect - the tea leaves point to a potential GOP wipeout.  OTOH, the public would have been better served if the influencers like the NEJM had voiced this level of sentiment last spring.

×
×
  • Create New...